Dr. Kurzrock was a panelist for The Forum’s discussion on Rare Cancers.
Dr. Razelle Kurzrock is known for developing one of the largest and best phase 1 clinical trials programs in the nation while at the University of Texas MD Anderson Cancer Center. A central theme of that program was the personalized medicine strategy, embodied in a protocol called PREDICT (Profile-Related Evidence Determining Individualized Cancer Therapy). This approach utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized chances for response.
At Moores Cancer Center at UC San Diego Health, Dr. Kurzrock’s charge is broad, including not just growing and innovating the Center’s clinical trials program, but also heading its newly established Center for Personalized Cancer Therapy. As a physician-scientist, she brings extraordinary expertise and experience in clinical research, business operations, regulatory operations, financial and budget planning, and administrative oversight, in addition to her world-recognized work in translational science. Dr. Kurzrock is also Chief of the Hematology & Oncology Division in the UC San Diego School of Medicine.
Dr. Kurzrock received her MD from the University of Toronto and has about 450 peer-reviewed publications and a uniquely strong record of competitive grant funding within the setting of phase I program building. She has been the principal investigator of the National Cancer Institute U01 Phase I Studies of Targeted Anti-Cancer Agents.
